Intellia Therapeutics (NTLA) Set to Release Quarterly Earnings on Thursday

Key Points

• Intellia Therapeutics is expected to report Q3 2026 results before market open on November 5. Analysts forecast a loss of $0.797 per share and revenue of $9.74 million.
• The company’s latest quarter showed a $0.80 per-share loss, revenue of $7.66 million—well below estimates—and a 46.4% year-over-year revenue decline. Analysts expect full-year and next-year losses of $3.21 and $2.32 per share, respectively.
• NTLA shares recently opened at $13.32, while the analyst consensus rating is Hold with a $20.57 price target; recommendations range from Strong Buy to Sell. Intellia is developing CRISPR-based therapies, including investigational treatments NTLA-2001 and NTLA-2002.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Intellia Therapeutics to announce earnings of ($0.7970) per share and revenue of $9.74 million for the quarter. Individuals can check the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 12:30 PM ET.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, hitting analysts' consensus estimates of ($0.80). Intellia Therapeutics had a negative return on equity of 57.79% and a negative net margin of 672.16%. The firm had revenue of $7.66 million during the quarter, compared to the consensus estimate of $12.98 million. During the same period in the prior year, the business earned ($0.98) EPS. The firm's revenue was down 46.4% on a year-over-year basis. On average, analysts expect Intellia Therapeutics to post ($3.21) EPS for the current fiscal year and ($2.32) EPS for the next fiscal year.

Intellia Therapeutics Stock Performance

Shares of NTLA opened at $13.32 on Thursday. The firm has a fifty day moving average of $12.23 and a 200-day moving average of $13.04. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -3.96 and a beta of 1.80. Intellia Therapeutics has a 1 year low of $7.95 and a 1 year high of $18.48.

Analyst Upgrades and Downgrades

Several brokerages have commented on NTLA. Citizens Jmp restated a "market outperform" rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, September 9th. HC Wainwright reissued a "buy" rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a report on Wednesday, September 9th. Citigroup restated a "market outperform" rating on shares of Intellia Therapeutics in a research report on Tuesday, August 25th. Wedbush lifted their target price on Intellia Therapeutics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Wednesday, September 9th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Intellia Therapeutics in a research report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have assigned a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $20.57.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a biotechnology company focused on developing potentially curative treatments using CRISPR-based gene-editing technology. The company is working to create therapies that can modify disease-causing genes inside the body, with the goal of addressing the underlying causes of serious genetic diseases rather than treating only their symptoms.

Intellia's pipeline has included NTLA-2001, an investigational in vivo gene-editing therapy designed to reduce production of transthyretin for the treatment of transthyretin amyloidosis, and NTLA-2002, an investigational therapy intended to target hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.